|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 01/22/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
The Budget Control Act of 2011 (Public Law 112-25): Sequester implementation
H.J. Res. 117, Continuing Appropriations Resolution, 2013: Provisions related to FDA funding, oversight, trade, prescription drug abuse, comparative effectiveness research, NIH funding, BARDA funding, PPACA implementation funding, 340B, IPAB, defense health accounts, biodefense funding/projects, and defense contracting
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Leo |
Farber |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Jeffrey |
Francer |
|
|
|
Sascha |
Haverfield-Gross |
|
|
|
Valerie |
Jewett |
|
|
|
Colleen |
Maloney |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Richard |
Smith |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
|
Nick |
Shipley |
|
Legislative Director - Rep. Jay Inslee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics
H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting
H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting
H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements
H.R. 4216, Foreign Counterfeit Protection Act: Provisions related to anti-counterfeiting
H.R. 6502, Life-Threatening Diseases Compassion through Combination Therapy Act: Provisions related to market exclusivity and expedited review
H.R. 6621, a bill to make technical corrections to the America Invents Act
H.R. 6654, Foreign Counterfeit Merchandise Prevention Act: Provisions related to trade enforcement
S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements
S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics
S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting
S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives
S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements
S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting
S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties
S. 3652, Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates
International intellectual property issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Matt |
Sulkala |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Leo |
Farber |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
David |
Korn |
|
|
|
Cara |
Moon |
|
|
|
James M. (Mit) |
Spears |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.1316, Stop Oxy Abuse Act of 2011: To limit the approval of any drug containing controlled-release oxycodone hydrochloride
H.R. 1513, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing
H.R. 2674, 340B Program Improvement Act: Provisions related to 340B
H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters
H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases
H.R. 4209, Patients Access to Treatments Act: To limit cost-sharing requirements applicable to prescription drugs in a specialty drug tier
H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003
H.R. 6288, Patient Choice Act: To permit provisional approval of fast track products
H.R. 6342, Compassionate Freedom of Choice Act: Provisions related to access to investigational drugs or devices for terminally ill patients
H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions relating to drug compounding
H.R. 6611, Patient Access to Drugs in Shortage Act of 2012: Promote public notification and provide incentives to reduce drug shortages
S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages
S. 810, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing
S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B
S. 2002, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies
S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters
S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation
S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases
S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform
Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking
Vaccine-related policy issues
Comparative effectiveness policy issues
General HHS and FDA related advocacy
Biopharmaceutical innovation policy issues
Pharmaceutical supply chain security issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Government Accountability Office (GAO), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
Nick |
Shipley |
|
Legislative Director - Rep. Jay Inslee |
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Leo |
Farber |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Jeffrey |
Francer |
|
|
|
Sascha |
Haverfield-Gross |
|
|
|
Valerie |
Jewett |
|
|
|
Ann |
Kaplan |
|
|
|
David |
Korn |
|
|
|
Kimberly |
Love |
|
|
|
Colleen |
Maloney |
|
|
|
Kendra |
Martello |
|
|
|
Cara |
Moon |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Richard |
Smith |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 5, Protecting Access to Healthcare Act: Provisions related to Independent Payment Advisory Board (IPAB)
H.R. 8, American Taxpayer Relief Act of 2012: Medicare and tax related provisions
H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB)
H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues
H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues
H.R. 4209, Patients Access to Treatments Act of 2012: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier
S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid
S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB)
S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues
S. 1699, Prescription Drug Cost Reduction Act: Provisions related to Medicare Part B, 340B, least costly alternative, and other provisions
Deficit reduction policy issues
Medicaid Program, Covered Outpatient Drugs rulemaking
Dual eligibles coordination policy issues
Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
Ann |
Kaplan |
|
|
|
Kimberly |
Love |
|
|
|
Colleen |
Maloney |
|
|
|
Kendra |
Martello |
|
|
|
Cara |
Moon |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Richard |
Smith |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 6083, Federal Agriculture Reform and Risk Management Act of 2012: Provisions related to WTO Brazil cotton dispute
H.R. 6156, Russia and Moldova Jackson-Vanik Repeal and Sergei Magnitsky Rule of Law Accountability Act of 2012: Trade relations provisions
S. 3240, Agriculture Reform, Food, and Jobs Act of 2012: Provisions related to WTO Brazil cotton dispute
S. 3285, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of the Russian Federation
Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health
Colombia Free Trade Agreement: Implementation issues related to intellectual property, market access and public health
Trans-Pacific Strategic Economic Partnership Agreement (TPP): Provisions related to intellectual property, market access and public health issues
Mexico and Canada IP and market access issues in context of invitation to join TPP negotiations
Turkey Market Access Issues
India innovation and market access issues
EU/US trade liberalizing agreement
Issues related to Special 301 and National Trade Estimate (NTE) submissions
Preference Programs
International market access and intellectual property issues
Anti-counterfeiting policy issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), State - Dept of (DOS), Natl Security Council (NSC), U.S. Trade Representative (USTR), White House Office, Executive Office of the President (EOP),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Leo |
Farber |
|
|
|
Robert |
Filippone |
|
|
|
David |
Korn |
|
|
|
Anne |
Pritchett |
|
|
|
James M. (Mit) |
Spears |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about/member-companies
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |